On the other hand, however, our study is the first where SNP rs3788205 in SLC19A1 was identified as a genetic marker of increased risk of ADRs in advanced NSCLC patients who received pemetrexed plus platinum treatment. The gene discussed is SLC19A1; the disease is non-small cell lung carcinoma.